IDENTIFYING AND TREATING AUTOIMMUNE NEUROLOGICAL DISORDERS
With
Associate Professor Sudarshini (Darshi) Ramanathan,
Neurologist & Head of Translational Neuroimmunology Group
Faculty of Medicine and Health
University of Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | April 2026
Associate Professor Sudarshini Ramanathan is a neurologist and clinician scientist whose work focuses on autoimmune neurological disorders. Her research has helped identify new neurological syndromes due to antibody-mediated demyelination and encephalitis, and improve diagnostic tools and treatment guidelines for patients with autoimmune diseases affecting the brain, spinal cord, muscles and nerves.
Associate Professor Ramanathan’s research program aims to improve our understanding of underlying disease pathogenesis with a focus towards ‘precision medicine’ in neuroimmunology – both with diagnosis and therapeutics. Her research focuses on defining the clinical, radiological, and immunophenotypic profiles of specific pathogenic autoantibodies; understanding what triggers autoimmunity and disruption of immune tolerance; and the cellular and humoural mechanisms of action of autoantibodies and how this might be translated into refining novel therapeutic approaches.
Her work thus far has resulted in the enhanced recognition of novel treatable neurological conditions, important biological insights into the pathophysiology of these disorders, and the development of diagnostic criteria and therapeutic approaches to improve outcomes in vulnerable patients who otherwise risk chronic disability.
Associate Professor Ramanathan heads the Translational Neuroimmunology Group at the Faculty of Medicine and Health, University of Sydney; and also runs a neuroimmunology clinic at Concord Hospital. She supervises and mentors a research team of PhD and Masters candidates, postdoctoral fellows, and clinician researchers. Her research has been recognised by the Leonard Cox Award for Excellence in Neuroscience research and the NSW Premier’s Prize Award for Early Career Researchers (Biological Sciences) in 2022.
Source: Supplied
https://orcid.org/0000-0002-0294-9768
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Role of metabolic dysfunction in advanced prostate cancer
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
-
DNA repair on the Fanconi anaemia pathway
Associate Professor Wayne Crismani is an internationally recognised expert in DNA repair, with a particular focus on Fanconi anaemia (FA)—a cancer-predisposition and bone marrow failure syndrome marked by extreme sensitivity to DNA damage. Based at St Vincent’s Institute in Melbourne, he leads a research program dedicated to understanding the genetic, cellular, and reproductive consequences of FA. He is currently supported by a Victorian Cancer Agency Mid-Career Fellowship and funding from the National Health and Medical Research Council.
